What are the key financial figures for Eli Lilly in this quarter?

The provided text is a directory listing for the 10-Q filing and does not contain the actual financial data. To find key financial figures such as revenue, net income, earnings per share, or cash flow, investors would need to access the full 10-Q report and review its financial statements and accompanying notes.

What are the main products or therapeutic areas driving Eli Lilly's performance?

This directory listing does not provide information on specific products or therapeutic areas. The full 10-Q report, particularly the Management's Discussion and Analysis section, would typically detail product performance, sales trends, and the impact of new drug development or regulatory approvals.

Are there any significant risks or uncertainties highlighted in this filing?

The directory listing itself does not mention specific risks or uncertainties. Such information, including factors that could affect future results, litigation, or regulatory matters, would be found in the full 10-Q filing, usually within the 'Risk Factors' or 'Legal Proceedings' sections, and Management's Discussion and Analysis.

What is the significance of this 10-Q filing for investors?

This 10-Q filing is significant because it provides investors with an updated view of Eli Lilly's financial health and operational performance for the second quarter of 1999. It allows investors to track the company's progress against previous periods, assess management's effectiveness, and make informed investment decisions based on the latest available financial and operational information.

LLY 10-Q Quarterly Report Q2 FY1999 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's (LLY) 10-Q filing for the period ending June 29, 1999, indicates a company focused on its core pharmaceutical operations. While the provided text is primarily a directory listing from the SEC EDGAR database and does not contain detailed financial statements or management discussion, it signifies that LLY is operating within regulatory frameworks and making its quarterly filings publicly accessible. Investors would typically look to the full financial statements within such a filing to assess revenue, profitability, cash flow, and any significant changes or trends impacting the company's financial health and future prospects. Without the actual financial data, a deeper analysis of LLY's performance for this quarter is not possible. However, the act of filing suggests ongoing business activity and compliance with reporting requirements. Investors would need to examine the full report to understand specific product performance, R&D pipeline updates, any new drug approvals or setbacks, and management's outlook on market conditions and competitive landscape.

Key Highlights

1Eli Lilly and Company (LLY) filed its 10-Q Quarterly Report for the period ending June 29, 1999.
2The filing was made with the U.S. Securities and Exchange Commission (SEC) on August 11, 1999, and is publicly available via the EDGAR database.
3This filing is a standard requirement for publicly traded companies and demonstrates ongoing operational and reporting compliance.
4The report would typically contain detailed financial statements, including balance sheets, income statements, and cash flow statements.
5Investors rely on these filings to assess the company's financial performance, strategic direction, and adherence to accounting standards.
6Without access to the full financial data within the 10-Q, specific operational highlights or financial metrics cannot be determined from the provided directory listing.
7The filing signifies LLY's continued engagement in its pharmaceutical business and its commitment to transparency with shareholders.

ELI LILLY & Co Quarterly Report for Q2 Ended Jun 30, 1999

Summary

Key Highlights

Frequently Asked Questions